Pregnant women are more susceptible to a decline in oral health-related quality of life (OHRQoL), influenced by a combination of cognitive-behavioral, physiological-pathological, and social support factors. Longitudinal studies have been conducted internationally on top of existing cross-sectional studies, exploring multidimensional determinants with an emphasis on quantitative methods. In contrast, domestic studies remain predominantly cross-sectional, with a limited scope of analysis on the contributing factors of OHRQoL. Current interventions targeting OHRQoL in pregnant women are scarce both domestically and globally. The Oral Health Impact Profile-14 (OHIP-14) is the most widely used tool for assessing OHRQoL in this population. This review synthesizes existing research progress on OHRQoL, aiming to provide insights for improving maternal OHRQoL and guiding future research.

Pregnant women are more susceptible to a decline in oral health-related quality of life (OHRQoL), influenced by a combination of cognitive-behavioral, physiological-pathological, and social support factors. Longitudinal studies have been conducted internationally on top of existing cross-sectional studies, exploring multidimensional determinants with an emphasis on quantitative methods. In contrast, domestic studies remain predominantly cross-sectional, with a limited scope of analysis on the contributing factors of OHRQoL. Current interventions targeting OHRQoL in pregnant women are scarce both domestically and globally. The Oral Health Impact Profile-14 (OHIP-14) is the most widely used tool for assessing OHRQoL in this population. This review synthesizes existing research progress on OHRQoL, aiming to provide insights for improving maternal OHRQoL and guiding future research.

Colorectal cancer is the most common malignant tumor of digestive tract, and BRAF V600E mutations occur in approximately 10% of patients with metastatic colorectal cancer (mCRC). Cancer patients harboring this mutation have a unique molecular profile and clinical phenotype; they show poor response to systemic chemotherapy, insensitivity to single BRAF inhibitor, and short survival rate. It is important to develop new therapeutic agents and clinical strategies to improve the prognosis of these patients. This review mainly introduces treatment methods for BRAF V600E-mutated mCRC and rationally derived combinations of targeted agents and immunotherapy.

Primary bone lymphoma (PBL) is a rare extranodal lymphoma that lacks specific clinical symptoms and imaging manifestations. Patients with PBL have been commonly treated with chemotherapy, radiotherapy or the combination of both. The prognosis of PBL is generally better than that of other extranodal lymphomas. This paper reviews the clinical symptoms, pathological diagnosis and treatment methods of PBL to deepen the understanding of the disease.